Full Breastfeeding and Allergic Diseases-Long-Term Protection or Rebound Effects?

Lars Libuda1,2, Birgit Filipiak-Pittroff2,3, Marie Standl4,5

  • 1Institute of Nutrition, Consumption and Health, Faculty of Natural Sciences, Paderborn University, Warburger Straße 100, 33098 Paderborn, Germany.

Nutrients
|June 28, 2023
PubMed

Insights

Early childhood eczema strongly predicts allergies into young adulthood. Breastfeeding protection against eczema diminishes over time, and a rebound effect was not confirmed in this long-term study.

Area of Science:

  • Pediatric Allergy and Immunology
  • Longitudinal Cohort Studies
  • Epidemiology

Background:

  • Previous research indicated breastfeeding protects against early eczema.
  • This protection may diminish in adolescence, raising questions about a potential rebound effect.

Purpose of the Study:

  • To evaluate the long-term impact of early eczema on allergy development until young adulthood.
  • To determine if early eczema influences the association between breastfeeding and allergies.

Main Methods:

  • Analysis of data from the GINIplus study up to 20 years (N=4058).
  • Assessment of physician-diagnosed atopic eczema, asthma, and rhinitis.
  • Modeling of adjusted odds ratios using generalized estimating equations.

Main Results:

  • Early eczema significantly predicted eczema, asthma, and rhinitis into young adulthood.
  • The association between early eczema and eczema decreased with age.
  • No significant association was found between breastfeeding and allergies from age 5 to 20.
  • Early eczema did not generally modify the breastfeeding-allergy link, except for rhinitis in specific subgroups.

Conclusions:

  • Early-onset eczema is a strong predictor of allergies persisting into young adulthood.
  • The protective effect of breastfeeding on eczema in infancy does not extend to young adulthood, and a rebound effect was not observed.

Related Concept Videos

Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
366
Allergic Reactions02:06

Allergic Reactions

Overview
27.8K
Allergic Drug Reactions01:27

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
898
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.7K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
357